NCT05351502 - A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 14, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

June 30, 2025

Conditions

Cancer

Interventions

DRUG

Nitric Oxide 25,000 ppm

Intratumoral injection of 25,000 gNO

DRUG

Nitric Oxide 50,000 ppm

Intratumoral injection of 50000 gNO

DRUG

Nitric Oxide 100,000 ppm

Intratumoral injection of 100,000 gNO

DRUG

Nitric Oxide selected dose

Intratumoral injection of selected does on gNO

Trial Locations (4)

RECRUITING

Soroka Medical Center, Beersheba

RECRUITING

Hadassah Ein-Karem, Jerusalem

RECRUITING

Sheba Medical Center, Ramat Ef‘al

RECRUITING

Sourasky Tel Aviv Medical Center, Tel Aviv